Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

53.81 -0.42 (-0.77%)
Streaming Delayed Price Updated: 1:59 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
84 85 Next >
News headline image
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
News headline image
The Pharmaceutical Industry Finds Itself At A Historical Crossroads ↗
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist ↗
These reliable dividend payers offer yields of 3.3% and better at recent prices. 
Via The Motley Fool
News headline image
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade ↗
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
News headline image
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation ↗
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA... 
Via Benzinga
News headline image
Is Bristol Myers Squibb Stock a Buy? ↗
The company is going through a rough patch. 
Via The Motley Fool
News headline image
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics ↗
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts... 
Via Benzinga
News headline image
Down 75%. Is Agenus Stock a Buy on the Dip? ↗
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
News headline image
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in April 2024 ↗
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
News headline image
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer ↗
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... 
Via Benzinga
News headline image
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗
These stocks could rocket higher, but they also present significant risks. 
Via The Motley Fool
News headline image
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
From Bristol Myers Squibb
Via Business Wire
News headline image
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts ↗
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
From Bristol Myers Squibb
Via Business Wire
News headline image
The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains ↗
Uncover strategic moves by three pharma giants poised to capture trends and fulfill emerging healthcare needs. 
Via InvestorPlace
News headline image
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details ↗
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati... 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in Q2 2024 ↗
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio ↗
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
Via InvestorPlace
News headline image
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease ↗
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April.... 
Via Benzinga
News headline image
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
From Bristol Myers Squibb
Via Business Wire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.